Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)
Abstract Purpose To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease with pneumonia. Methods A randomized, double blind, placebo-controlled clinical trial of favipiravir in patients with COVID-19 pneumonia was conducted in three Sp...
Main Authors: | Juan P. Horcajada, Rebeca Aldonza, Mónica Real, Silvia Castañeda-Espinosa, Elena Sendra, Joan Gomez-Junyent, Inmaculada López-Montesinos, Silvia Gómez-Zorrilla, Silvia Briansó, Montserrat Duran-Taberna, Andrés Fernández, Cristina Tarragó, Teresa Auguet-Quintillá, the COVID-MAR Research group, the COVID-HJ23 group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-02-01
|
Series: | Pneumonia |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41479-023-00124-6 |
Similar Items
-
Effect of favipiravir and an anti-inflammatory strategy for COVID-19
by: Hitoshi Yamamura, et al.
Published: (2020-07-01) -
Hematological Malignancy Patients, COVID-19, and Favipiravir
by: Rujittika Mungmunpuntipantip, et al.
Published: (2021-12-01) -
Use of Favipiravir in Covid-19 Patients: A Narrative Review
by: Vitarani Dwi Ananda Ningrum, et al.
Published: (2024-05-01) -
Evaluation of the effect of favipiravir on patients with COVID-19
by: Alireza Kamali, et al.
Published: (2023-02-01) -
Follow-up of Favipiravir-Induced Nail Fluorescence: Implications for Nail and Drugs
by: Hüsna Güder, et al.
Published: (2023-01-01)